GR3034625T3 - Tricyclic dicarbonyl derivatives - Google Patents
Tricyclic dicarbonyl derivativesInfo
- Publication number
- GR3034625T3 GR3034625T3 GR20000402311T GR20000402311T GR3034625T3 GR 3034625 T3 GR3034625 T3 GR 3034625T3 GR 20000402311 T GR20000402311 T GR 20000402311T GR 20000402311 T GR20000402311 T GR 20000402311T GR 3034625 T3 GR3034625 T3 GR 3034625T3
- Authority
- GR
- Greece
- Prior art keywords
- lower alkyl
- pct
- disease
- amino
- signify
- Prior art date
Links
- 125000004989 dicarbonyl group Chemical group 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000004429 atom Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 208000036626 Mental retardation Diseases 0.000 abstract 1
- 208000001089 Multiple system atrophy Diseases 0.000 abstract 1
- 208000008238 Muscle Spasticity Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 206010047163 Vasospasm Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- -1 hydroxy, amino Chemical group 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000035987 intoxication Effects 0.000 abstract 1
- 231100000566 intoxication Toxicity 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000018198 spasticity Diseases 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 125000005505 thiomorpholino group Chemical group 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH160294 | 1994-05-24 | ||
| CH47795 | 1995-02-17 | ||
| PCT/EP1995/001856 WO1995032205A1 (en) | 1994-05-24 | 1995-05-16 | Tricyclic dicarbonyl derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR3034625T3 true GR3034625T3 (en) | 2001-01-31 |
Family
ID=25684688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20000402311T GR3034625T3 (en) | 1994-05-24 | 2000-10-13 | Tricyclic dicarbonyl derivatives |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5688803A (el) |
| EP (1) | EP0760819B1 (el) |
| JP (1) | JP2828506B2 (el) |
| CN (1) | CN1044245C (el) |
| AT (1) | ATE194841T1 (el) |
| AU (1) | AU688515B2 (el) |
| BR (1) | BR9507672A (el) |
| CA (1) | CA2189776A1 (el) |
| DE (1) | DE69518075T2 (el) |
| DK (1) | DK0760819T3 (el) |
| ES (1) | ES2149989T3 (el) |
| GR (1) | GR3034625T3 (el) |
| NZ (1) | NZ287413A (el) |
| PT (1) | PT760819E (el) |
| RU (1) | RU2145606C1 (el) |
| WO (1) | WO1995032205A1 (el) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5243049A (en) * | 1992-01-22 | 1993-09-07 | Neurogen Corporation | Certain pyrroloquinolinones: a new class of GABA brain receptor ligands |
| US5955465A (en) * | 1996-03-22 | 1999-09-21 | Neurogen Corporation | 1,2,4-triazolo 4,3-c!quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones |
| GB2346883B (en) * | 1996-09-02 | 2001-02-14 | Lilly Industries Ltd | GluR5 receptor binding assay |
| FR2773153A1 (fr) * | 1997-12-29 | 1999-07-02 | Rhone Poulenc Agrochimie | Nouveaux composes fongicides |
| DE19910986C2 (de) * | 1999-03-11 | 2001-06-07 | Aga Ab | Verwendung von Xenon bei der Behandlung von Neurointoxikationen |
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| WO2001046190A1 (fr) * | 1999-12-22 | 2001-06-28 | Kyorin Pharmaceutical Co., Ltd. | Composes tricycliques et sels d'addition de ceux-ci |
| DE10004572A1 (de) * | 2000-02-02 | 2001-08-09 | Boehringer Ingelheim Pharma | Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| HU227197B1 (en) * | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| GB0223730D0 (en) * | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
| CN100347173C (zh) * | 2002-11-22 | 2007-11-07 | 活跃生物技术股份公司 | 具有免疫调制活性的吡唑并喹啉 |
| RU2257385C2 (ru) * | 2003-08-26 | 2005-07-27 | ООО "Исследовательский институт химического разнообразия" | 1,3-диоксо -2,3-дигидро-1h-пирроло[3,4-c]хинолины (варианты), фармацевтические композиции (варианты), способ их получения (варианты) и способы лечения (варианты) |
| EP1719771A1 (en) | 2004-02-19 | 2006-11-08 | Takeda Pharmaceutical Company Limited | Pyrazoloquinolone derivative and use thereof |
| PT1740584E (pt) * | 2004-04-28 | 2009-03-10 | Takeda Pharmaceutical | Derivado de quinolina fundida e sua utilização |
| JO3077B1 (ar) * | 2005-07-28 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينولين مضادة للبكتيريا |
| TW200806670A (en) * | 2006-04-25 | 2008-02-01 | Merck & Co Inc | Inhibitors of checkpoint kinases |
| US7907679B2 (en) * | 2007-01-12 | 2011-03-15 | General Dynamics C4 Systems, Inc. | Methods and systems for acquiring signals using coherent match filtering |
| US8139680B2 (en) | 2007-01-12 | 2012-03-20 | General Dynamics C4 Systems, Inc. | Signal acquisition methods and apparatus in wireless communication systems |
| WO2008109613A1 (en) * | 2007-03-05 | 2008-09-12 | Wyeth | Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors |
| WO2008154447A1 (en) * | 2007-06-08 | 2008-12-18 | Helicon Therapeutics, Inc. | Therapeutic pyrazolonaphthyridine derivatives |
| CA2720464C (en) * | 2008-04-04 | 2017-05-02 | Forskarpatent I Syd Ab | Gabaa receptor modulators |
| DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| WO2009139916A1 (en) * | 2008-05-16 | 2009-11-19 | Synta Pharmaceuticals Corp. | Tricyclic triazole compounds that modulate hsp90 activity |
| US20110212053A1 (en) * | 2008-06-19 | 2011-09-01 | Dapeng Qian | Phosphatidylinositol 3 kinase inhibitors |
| CA2737587C (en) | 2008-11-14 | 2016-08-09 | F. Hoffmann-La Roche Ag | Quinazoline derivatives as nk3 receptor antagonists |
| US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| WO2011146591A1 (en) | 2010-05-19 | 2011-11-24 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| US9278093B2 (en) | 2012-04-04 | 2016-03-08 | Merck Sharp & Dohme Corp. | Aldosterone synthase inhibitors |
| EP2929169B1 (en) | 2012-12-04 | 2019-02-13 | Volvo Truck Corporation | Method and system for controlling fuel injection |
| CN103073547A (zh) * | 2013-02-06 | 2013-05-01 | 上海药明康德新药开发有限公司 | 一种(3aS,9bR)-叔丁基-3,3a,4,5-四氢吡咯[3,4-c]喹啉-2(9bH)酯的合成方法 |
| JP6244353B2 (ja) | 2013-04-05 | 2017-12-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピリジニルピラゾロキノリン化合物 |
| ES2645149T3 (es) | 2013-04-05 | 2017-12-04 | Eisai R&D Management Co., Ltd. | Sal de derivado de pirazoloquinolina y cristal de esta |
| CN104447736B (zh) * | 2014-10-14 | 2016-06-08 | 雅安职业技术学院 | 一种veranamine的合成方法 |
| EP3632438B1 (en) | 2017-06-01 | 2023-08-23 | Eisai R&D Management Co., Ltd. | Lewy body disease therapeutic agent containing pyrazoloquinoline derivative |
| WO2018221546A1 (en) | 2017-06-01 | 2018-12-06 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition comprising pde9 inhibitor |
| KR102627790B1 (ko) | 2017-06-01 | 2024-01-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피라졸로퀴놀린 유도체와 메만틴을 병용한 치매 치료제 |
| SG10202113198TA (en) | 2017-06-01 | 2021-12-30 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
| WO2024012554A1 (zh) * | 2022-07-14 | 2024-01-18 | 上海日馨医药科技股份有限公司 | Tpk激动剂及使用其治疗神经退行性疾病的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL66835A (en) * | 1981-09-24 | 1988-05-31 | Roussel Uclaf | 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them |
| US4713383A (en) * | 1984-10-01 | 1987-12-15 | Ciba-Geigy Corporation | Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses |
| DE69113115T2 (de) * | 1990-05-31 | 1996-06-13 | Merck Sharp & Dohme | Dioxo-tetrahydrochinolinderivate. |
| JPH05271200A (ja) * | 1991-05-22 | 1993-10-19 | Egyt Gyogyszervegyeszeti Gyar | ６，７−ジクロロ−１，５−ジヒドロ−イミダゾ〔２，１−ｂ〕キナゾリン−２〔３Ｈ〕−オンの製造方法 |
| US5243049A (en) | 1992-01-22 | 1993-09-07 | Neurogen Corporation | Certain pyrroloquinolinones: a new class of GABA brain receptor ligands |
-
1995
- 1995-05-16 JP JP7530032A patent/JP2828506B2/ja not_active Expired - Fee Related
- 1995-05-16 BR BR9507672A patent/BR9507672A/pt not_active IP Right Cessation
- 1995-05-16 US US08/737,240 patent/US5688803A/en not_active Expired - Fee Related
- 1995-05-16 WO PCT/EP1995/001856 patent/WO1995032205A1/en active IP Right Grant
- 1995-05-16 EP EP95920816A patent/EP0760819B1/en not_active Expired - Lifetime
- 1995-05-16 DE DE69518075T patent/DE69518075T2/de not_active Expired - Fee Related
- 1995-05-16 CA CA002189776A patent/CA2189776A1/en not_active Abandoned
- 1995-05-16 DK DK95920816T patent/DK0760819T3/da active
- 1995-05-16 AU AU26130/95A patent/AU688515B2/en not_active Ceased
- 1995-05-16 PT PT95920816T patent/PT760819E/pt unknown
- 1995-05-16 NZ NZ287413A patent/NZ287413A/en unknown
- 1995-05-16 AT AT95920816T patent/ATE194841T1/de not_active IP Right Cessation
- 1995-05-16 CN CN95193244A patent/CN1044245C/zh not_active Expired - Fee Related
- 1995-05-16 ES ES95920816T patent/ES2149989T3/es not_active Expired - Lifetime
- 1995-05-16 RU RU96124496/04A patent/RU2145606C1/ru not_active IP Right Cessation
-
2000
- 2000-10-13 GR GR20000402311T patent/GR3034625T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE194841T1 (de) | 2000-08-15 |
| EP0760819B1 (en) | 2000-07-19 |
| CA2189776A1 (en) | 1995-11-30 |
| US5688803A (en) | 1997-11-18 |
| BR9507672A (pt) | 1997-08-19 |
| DE69518075T2 (de) | 2001-03-22 |
| RU2145606C1 (ru) | 2000-02-20 |
| AU688515B2 (en) | 1998-03-12 |
| CN1044245C (zh) | 1999-07-21 |
| PT760819E (pt) | 2000-11-30 |
| DK0760819T3 (da) | 2000-10-09 |
| JP2828506B2 (ja) | 1998-11-25 |
| WO1995032205A1 (en) | 1995-11-30 |
| ES2149989T3 (es) | 2000-11-16 |
| JPH09506634A (ja) | 1997-06-30 |
| DE69518075D1 (de) | 2000-08-24 |
| EP0760819A1 (en) | 1997-03-12 |
| AU2613095A (en) | 1995-12-18 |
| CN1149295A (zh) | 1997-05-07 |
| NZ287413A (en) | 1998-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR3034625T3 (en) | Tricyclic dicarbonyl derivatives | |
| CN102066384B (zh) | 作为α-7烟碱乙酰胆碱受体配体的奎宁环化合物 | |
| CA2783727A1 (en) | 2-arylimidazole derivatives as pde10a enzyme inhibitors | |
| CN108602818B (zh) | 吡唑稠环类衍生物、其制备方法及其在治疗癌症，炎症和免疫性疾病上的应用 | |
| KR20180095625A (ko) | 신규한 화합물 | |
| YU27902A (sh) | Derivati benzodiazepina | |
| AU695045B2 (en) | Heteroaromatic oxazole compounds and use thereof | |
| WO2001021160B1 (en) | Carboxymide and aniline derivatives as selective inhibitors of pathogens | |
| NZ286103A (en) | use of pyrrolo-and pyrazolopyrimidine derivatives to treat various neuronal disorders | |
| DE69222096D1 (de) | Tetrahydropyrrolo[1,2-a]Pyrazin-4-Spiro-3'-Pyrrolidin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
| AU2003284632A1 (en) | Isoquinoline compounds and medicinal use thereof | |
| CA2042113A1 (en) | Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors | |
| DE69415341D1 (de) | Kondensierte tricyclische heteroaromatische derivate als liganden des dopamin-rezeptor-subtyps | |
| TR199900946T2 (xx) | 2-Metoksifenilpiperazin t�revleri. | |
| IE960775L (en) | Arylalkylamine having anticonvulsant and neuroprotective properties | |
| JO2307B1 (en) | Papermidine derivatives | |
| JPWO2002042312A1 (ja) | 新規カルバペネム誘導体 | |
| WO2001007023A3 (en) | Azetidine compounds in cns and eye diseases | |
| IE67525B1 (en) | Derivatives of Penem | |
| CN117800969A (zh) | 肿瘤坏死因子受体复合物抑制剂及其用途 | |
| AU2178199A (en) | Azetidinecarboxamide derivatives for the treatment of cns disorders | |
| WO2025147600A1 (en) | Amino quinoline compounds and uses thereof | |
| AU675889B2 (en) | Pyridazinone derivatives, processes for production thereof | |
| WO2001007022A3 (en) | Azetidine compounds in cns and eye diseases | |
| CA2043229A1 (en) | Pyrido[3,4-b]pyrrolo[1,2-e] [1,4,5]oxadiazepines and related analogs, a process for their preparation and their use as medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ML | Lapse due to non-payment of fees |